Stay updated on KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial
Sign up to get notified when there's something new on the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page.

Latest updates to the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4, indicating a new version of the page. This represents a minor update to the page's documentation/history rather than substantive changes to the study information.SummaryDifference0.0%

- Check16 days agoChange DetectedEnrollment status updated to Completed on 2026-05-11, replacing the prior Active, not recruiting status. This signals that the study has finished enrolling participants and is moving toward completion and results submission.SummaryDifference0.1%

- Check22 days agoChange DetectedAdded a Tampa, Florida site (33614-2846) with status Completed. Removed a Tampa site (33614-2869) that was Active, not recruiting, reflecting a change in recruitment status at that location.SummaryDifference0.1%

- Check30 days agoChange DetectedThis update expands the number of locations from 119 to 154 by adding numerous sites across multiple countries, including the UK, Switzerland, Poland, Peru, Chile, China, and more. It reflects a broader recruitment footprint across the study network.SummaryDifference8%

- Check37 days agoChange DetectedThe study record was updated with new date/version information and a location change in Florida (adding/reflecting a Stuart, FL site while an earlier Okeechobee, FL listing was removed). A revision/version label also changed (from v3.5.0 to v3.5.2).SummaryDifference0.3%

- Check59 days agoChange DetectedSponsor name updated from Karuna Therapeutics to Karuna Therapeutics, Inc., a Bristol Myers Squibb company.SummaryDifference0.1%

Stay in the know with updates to KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page.